Pixium Vision

12/02/2024

https://www.touchophthalmology.com/macular-degeneration/journal-articles/subretinal-photovoltaic-implant-prima-provides-central-vision-in-subjects-with-geographic-atrophy-due-to-age-related-macular-degeneration/

Age-related macular degeneration (AMD) is one of the main causes of irreversible vision loss in ageing populations worldwide.1 In 2019, the US recorded 1.49

26/01/2024

Proud to read Lloyd Diamond's interview with MD+DI and Medsider's Scott Nelson, discussing the significance of networking for medical device startups. Lloyd emphasizes the importance of cultivating relationships with investors who offer more than just financial support. In numerous instances, he notes, wisdom proves to be a more valuable asset than venture capital alone!

https://www.mddionline.com/startups/why-networking-is-crucial-for-medical-device-startups

FastWave Medical’s co-founder and CEO, Scott Nelson shows us why the most important ingredient in having a successful startup revolves around networking.

21/11/2023

🌟 👁️ Pixium's groundbreaking technology merging visual processing, micro-electronics, opto-electronics, and advanced software, aims to restore vision for patients with severe central vision impairment due to specific retinal diseases.

This cutting-edge development is the result of extensive collaboration and multidisciplinary expertise. Since 2014, Pixium has partnered with Stanford University to advance the technology behind the Prima system. Key collaborators also include Institut de la Vision, Hôpital national des Quinze-Vingts in Paris, Moorfields Eye Hospital, London, and a host of leading research institutes and centers of clinical excellence dedicated to eye health.

🤝This collective effort underscores the importance of shared knowledge and cooperation in achieving remarkable technological leaps in vision restoration.

10/11/2023

Muqit (UK), Yannick Le Mer (F), Frank G. Holz (D) et al around the subretinal PRIMA microchip for geographic atrophy in age-related is now available on PubMed.

🔍 The study focused on long-term observations of macular thickness after the implantation. The results? This innovative implant not only provides a safe and effective alternative to more invasive procedures but also maintains its efficacy over a considerable period.

👁️ Unlike complex brain implants requiring skull incision with a cranial drill and bone flap removal, this minimally invasive technique specifically targets the back of the eye. It electrically stimulates the inner retinal neurons to restore partial vision. What's impressive is the stability of the implant-to-cell distance and the overall minimal changes in retinal thickness, which stabilizes just three months post-operation. The findings reveal that after the initial period following surgery, there's no significant adverse structural or functional impact, maintaining retinal thickness and health over 36 months. This is a significant reassurance for patients and practitioners alike, suggesting a promising future for those suffering from AMD.

💡 This research emphasizes the incredible potential of targeted, minimally invasive surgical techniques in treating complex conditions like AMD.

For more details, read the article here: https://pubmed.ncbi.nlm.nih.gov/36174540/

18/10/2023

Raising awareness and informing the general public about visual disorders is at the heart of Pixium Vision's priorities. Brian Burg, Director of R&D at Pixium Vision, recently took part in a web conference organized by Pharmaceutiques and presented by Herve Requillart on the theme of visual health.

Pixium blends visual processing, micro-electronics, opto-electronics, and smart software to reinstate vision for patients with severe central vision impairment due to certain retinal diseases.

If you would like to learn more about our technology or watch a recording of Brian's interview, contact us directly! https://www.pixium-vision.com/contact-us/

25/09/2023

Celebrated on the last Sunday of September, World Retina Day spotlights retinal health's critical importance. The day is dedicated to:

- Understanding retinal degeneration and its impact on vision and life quality.
- Recognizing daily challenges for the visually impaired.
- Stressing the necessity of routine eye examinations and community support.
- Highlighting the pivotal role of research and innovation in elevating life quality.

At Pixium, being at the vanguard of addressing vision loss, we deeply resonate with these objectives. Pixium blends visual processing, micro-electronics, opto-electronics, and smart software to reinstate vision for patients with severe central vision impairment due to certain retinal diseases.

13/09/2023

Our CEO Lloyd Diamond will be presenting at LSI - Life Science Intelligence™'s upcoming LSI Europe '23 Emerging Medtech Summit.

Don't miss his talk for a chance to learn more about investing in a late clinical stage bionic vision company with a $1.6bn+ market opportunity.

Time: 10:45-10:54 am (Track 1)
Date: September 19, 2023

06/09/2023

👁️ The health repercussions for individuals experiencing severe vision impairment or blindness extend beyond the immediate loss of vision. Not only does not being able to see clearly significantly impact quality of life, but it also brings about several other health-related concerns:

❗️An elevated risk of depression: Without sight, many face challenges in social interactions, mobility, and daily tasks, leading to feelings of isolation and a higher propensity for depressive disorders.
❗️An increased likelihood of early admission to nursing homes and long-term care facilities: Due to the decreased ability to independently manage daily activities and the potential lack of familial or community support, many blind individuals find themselves in need of assisted living earlier in life.
❗️A doubled risk of premature death: The cumulative effects of the challenges faced, both psychological and physical, contribute to a significantly shortened life expectancy for those who are blind.

These realities underscore the importance and urgency of researching and developing innovative treatments for conditions impairing vision. The benefits of such advancements would not only restore sight but potentially address these auxiliary health concerns as well.

23/08/2023

Don't miss us at the LSI Europe Emerging MedTech Summit 2023, taking place in Barcelona, September 18-22.

Our CEO Lloyd Diamond will be presenting the latest news from Pixium Vision, including an update on our pivotal clinical trial.

We're looking forward to connecting with everyone at the event!

16/08/2023

Age-related macular degeneration (AMD) is estimated to affect 196 million globally. It is the leading cause of severe vision loss and legal blindness in people over the age of 65 in North America and Europe. Approximately 10%–15% of all AMD patients will eventually develop the wet form of AMD. Yet, while treatments have been developed for wet AMD, those with dry AMD have fewer options.

Pixium Vision is paving the way for treatments for severe vision loss in dry AMD patients using neurostimulation technology. Pixium's innovative blend of visual processing, micro-electronics, opto-electronics, and intelligent software seeks to restore vision to retinal disease patients suffering from profound central vision impairment.

We are proud to have received FDA breakthrough device designation, and are currently concluding our one year follow up on our EU Pivotal study.

08/08/2023

👁️ A healthy human eye has three types of cone cells, each of which can register about 100 different color shades, amounting to around a million combinations. However, globally 285 million people are visually impaired and 39 million people suffer from complete blindness.

🌈 Our goal at Pixium is to help those with retinal diseases experience the richness of vision once again.

Currently in development for Dry AMD (Geographic Atrophy), ophthalmic experts recommended that the Prima chip be developed for retinal disease patients suffering from profound central vision impairment defined as Logmar ≥1.2.

Follow us to stay updated on our work!

03/08/2023

📢 We will be attending the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference on August 16, 2023.

Pixium Vision harnesses rapid advances in
✔️visual processing
✔️micro-electronics
✔️opto-electronics
✔️neurobiology
✔️intelligent software algorithms
to restore vision to retinal disease patients refractive to medical treatment and suffering from profound central vision impairment (Logmar ≥1.2).

🔬 Developed at Stanford University, Pixium’s PRIMA retinal microchip is 2-mm wide, 30-μm thin, and packs 378 pixels, each 100 μm in diameter to deliver photovoltaic neurostimulation to the subretinal atrophic area of absolute scotoma. The chip is minimally invasive and can be implanted in less than 2 hours. Currently in development for Geographic atrophy (GA), ophthalmic experts in Pixium’s Advisory Board recommended that the Prima retinal neurostimulation chip may be able to help patients with profound vision loss across a range of non-orphan and orphan indications.

👏If you’re attending the conference make sure to reach out to our CEO Lloyd Diamond via our virtual booth, or tune into his company presentation Wednesday August 16 at 7:00am.

Visit the conference website for registration: https://hcwevents.com/ophthalmologyconference/